Clinical trial · no report yet · Phase 3
SORENTO
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
- NCT05050942 ↗
- Active not recruiting
- Camurus AB
- 12 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 8 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- CAM2029; Octreotide LAR; Lanreotide ATG
- Arms
- CAM2029 · Experimental
- Octreotide LAR or lanreotide ATG · Active comparator
- Enrollment
- 332
- Primary outcomes
- Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)
- Sponsor
- Camurus AB
- Start
- Oct 22, 2021
- Primary completion
- Nov 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05050942 · updated Jul 28, 2026
Publications
linked from the registry- Singh S, Ferone D, Capdevila J, Chan JA, de Herder WW, Halperin D, Mailman J, Hellstrom L, Liedman H, Svedberg A, Tiberg F. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials. 2024 Jan 16;25(1):58. doi: 10.1186/s13063-023-07834-8. PubMed 38229199